Comparative efficacy of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists with or without dexamethasone for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy (HEC): a network meta-analysis [PDF]
PeerJObjective This network meta-analysis evaluated the efficacy of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists, with or without Dexamethasone (D), for preventing chemotherapy-induced nausea and vomiting (CINV) in patients undergoing highly emetogenic ...
Hongxia Xu +5 more
doaj +3 more sources
The impact of 5-hydroxytryptamine-receptor antagonists on chemotherapy treatment adherence, treatment delay, and nausea and vomiting [PDF]
Cancer Management and Research, 2015 Swetha Rao Palli,1 Michael Grabner,1 Ralph A Quimbo,1 Hope S Rugo2 1HealthCore, Wilmington, DE, 2University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA Purpose: To determine the incidence of ...
Palli SR, Grabner M, Quimbo RA, Rugo HS
doaj +4 more sources
Impact of 5-HT3 receptor antagonists on chemotherapy-induced nausea and vomiting: a retrospective cohort study [PDF]
BMC Health Services Research, 2012 Background 1st generation 5-hydroxytryptamine receptor antagonists (5-HT3 RAs), and palonosetron, a 2nd generation 5-HT3 RA, are indicated for the prevention of chemotherapy (CT)-induced nausea and vomiting (CINV) associated with moderately (MEC) and ...
Lin Swu-Jane +4 more
doaj +2 more sources
A Case of Possible Infusion-Related Reactions Caused by Palonosetron [PDF]
Case Reports in OncologyIntroduction: An infusion-related reaction (IRR) is an adverse event that typically occurs when cytotoxic drugs or monoclonal antibodies are administered.
Toru Kadono +4 more
doaj +2 more sources
Comparison of efficacy and safety between palonosetron and ondansetron to prevent postoperative nausea and vomiting in patients undergoing laparoscopic surgery: a systematic review and meta-analysis [PDF]
Journal of Minimally Invasive SurgeryPurpose: Postoperative nausea and vomiting (PONV) is a prevalent and distressing complication, especially in laparoscopic surgeries. This review compares the efficacy and safety of palonosetron and ondansetron in preventing PONV after laparoscopic ...
Jitendra Kumar +11 more
doaj +2 more sources
Hospital Pharmacy, 2015 Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Dennis J, Cada +2 more
openaire +3 more sources
Evaluation of the ability of continuous palonosetron infusion, using a patient-controlled analgesia device, to reduce postoperative nausea and vomiting [PDF]
Korean Journal of Anesthesiology, 2014 BackgroundThe efficacy of palonosetron in preventing postoperative nausea and vomiting (PONV), as well as chemotherapy-induced nausea and vomiting, has already been demonstrated in multiple clinical studies.
Ji Won Kang, Soo Kyoung Park
doaj +1 more source
Analgesic effects of palonosetron in the intravenous propofol injection [PDF]
Korean Journal of Anesthesiology, 2014 BackgroundPropofol is a good induction agent, but it has the disadvantage of causing pain on intravenous injection. The incidence of propofol-induced pain is approximately 70%.
Han-Bom Ryu, Su-Jin Kim
doaj +1 more source
The effect of palonosetron on rocuronium-induced withdrawal movement
Brazilian Journal of Anesthesiology, 2017 Background: Rocuronium causes pain and withdrawal movement during induction of anesthesia. In this study, palonosetron was investigated to have analgesic effect on the reduction of rocuronium-induced withdrawal movement.
Ki-Bum Park +5 more
doaj +3 more sources
The comparative study to evaluate the effect of palonosetron monotherapy versus palonosetron with dexamethasone combination therapy for prevention of postoperative nausea and vomiting [PDF]
Korean Journal of Anesthesiology, 2012 Background5-hydroxytryptamine type 3 (5-HT3) receptor antagonists are effective and safe on postoperative nausea and vomiting (PONV). Palonosetron, the newest 5-HT3 antagonist, has potent antiemetic property.
Jung Woo Park +7 more
doaj +1 more source